4Skarlowsky JA, draghi DC ,Jones ME, et al. Urveillanee for antimierobial suseeptibil-ity among clinical isolates of pseudomonasaerugino 6a and acinetobacter baumannii fromhospitalized patients in the United States, 1998 to 2001 [ J ]. Antimiewb Agents Chemother, 2003 ( 5 ) : 1681- 1688.
7Martinez-Martinez L, Herandez-Alles S, Alberti S, et al. In vivo selection of porin-deficient mutants of Klebsilla pncumoniae with increased resistance to cefoxitin and expended-spcetrum cephalosporins [ J ]. Antumierob Agents Chemothet, 1996 (40) : 342 - 348.
6National Committee for Clinical Laboratory Standard, 2002. Performance Standards for Antimicrobial Susceptibility Testing. NCCLS, Wayne, Pa.
7Rhomberg PR, Jones RN , MYSTIC Study Group. Antimicrobial spectrum of activity for meropenem and nine broad spectrum antimicrobials:report from the MYSTIC Program (2002) in North America. Diagn Microbiol Infect Dis, 2003,47:365-372.
8Pfaller MA, Jones RN , MYSTIC Study Group. Antimicrobial susceptibility of inducible Amp C β-lactamase-producing Enterobacteriaceae from the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) Programme, Europe 1997-2000. Int J Antimicrob Agents, 2002,19:383-388.
9Sader HS, Biedenbach DJ ,Jones RN. Global patterns of susceptibility for 21 commonly utilized antimicrobial agents tested against 48440 Enterobacteriaceae in the SENTRY Antimicrobial Surveillance Program (1997-2000). Diagn Microbiol Infect Dis, 2003,47:361-364.
10Sader HS, Gales AC, Pfaller MA, et al. Pathogen frequency and resistance patterns in Brazilian hospitals:summary of results from three years of the SENTRY Antimicrobial Surveillance Program. Braz J Infect Dis, 2001,5:200-214.
